Incyte Corp Appoints New CMO, Director; CMO Departs
Ticker: INCY · Form: 8-K · Filed: Jan 10, 2025 · CIK: 879169
Sentiment: neutral
Topics: executive-changes, board-of-directors, personnel
Related Tickers: INCY
TL;DR
INCY shakes up leadership: new CMO, new director, old CMO transitions to consulting.
AI Summary
On January 6, 2025, Incyte Corporation (INCY) reported changes in its executive and director roles. The company announced the election of Dr. Paul J. Gaydos as a new Class III director and the appointment of Dr. Steven Stein as Chief Medical Officer. Additionally, Dr. Barry P. Flavin has stepped down as Chief Medical Officer but will continue as a consultant.
Why It Matters
These executive and director changes could signal shifts in leadership strategy and medical development focus for Incyte Corporation.
Risk Assessment
Risk Level: low — The filing details routine executive and director changes without any indication of financial distress or significant operational disruption.
Key Players & Entities
- Incyte Corporation (company) — Registrant
- Dr. Paul J. Gaydos (person) — Elected Class III Director
- Dr. Steven Stein (person) — Appointed Chief Medical Officer
- Dr. Barry P. Flavin (person) — Stepped down as Chief Medical Officer
FAQ
Who has been elected as a new director for Incyte Corporation?
Dr. Paul J. Gaydos has been elected as a new Class III director.
Who is the new Chief Medical Officer at Incyte Corporation?
Dr. Steven Stein has been appointed as the new Chief Medical Officer.
What is Dr. Barry P. Flavin's new role after stepping down as Chief Medical Officer?
Dr. Barry P. Flavin will continue to serve as a consultant for Incyte Corporation.
What is the effective date of the earliest event reported in this 8-K filing?
The earliest event reported is dated January 6, 2025.
What is Incyte Corporation's state of incorporation?
Incyte Corporation is incorporated in Delaware.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2025-01-10 08:11:23
Filing Documents
- incy-20250106.htm (8-K) — 21KB
- 0000879169-25-000011.txt ( ) — 140KB
- incy-20250106.xsd (EX-101.SCH) — 2KB
- incy-20250106_lab.xml (EX-101.LAB) — 21KB
- incy-20250106_pre.xml (EX-101.PRE) — 12KB
- incy-20250106_htm.xml (XML) — 3KB
From the Filing
incy-20250106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 INCYTE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-12400 94-3136539 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 1801 Augustine Cut-Off Wilmington , DE 19803 (Address of principal executive offices) (Zip Code) ( 302 ) 498-6700 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of exchange on which registered Common Stock, $.001 par value per share INCY The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b—2 of the Securities Exchange Act of 1934 ( 240.12b—2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 6, 2025, Barry P. Flannelly, Executive Vice President, General Manager, North America of Incyte Corporation (the "Company"), announced his retirement from the Company and stepped down from that role on that date, effective with the commencement of employment of his successor. Dr. Flannelly will remain employed by the Company through July 31, 2025 to assist with the transition of his responsibilities. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 10, 2025 INCYTE CORPORATION By: /s/ Sheila A. Denton Sheila A. Denton Executive Vice President and General Counsel 3